In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Zymeworks (ZYME – Research Report), with a price target of $21.00. The company’s shares closed yesterday at $11.05.
Willey covers the Healthcare sector, focusing on stocks such as Exelixis, Geron, and Zymeworks. According to TipRanks, Willey has an average return of 12.3% and a 43.12% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zymeworks with a $13.50 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $13.14 and a one-year low of $6.02. Currently, Zymeworks has an average volume of 552.7K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZYME in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zymeworks (ZYME) Company Description:
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
Read More on ZYME:
